P21

P21 (Peptide 021) is a synthetic neurotrophic tetra-peptide derived from ciliary neurotrophic factor that promotes neurogenesis and has been investigated for treating neurological disorders such as Alzheimer's disease.

Brief glance

The primary outcome is Cognitive, but it's also used for Longevity. This compound is considered a Peptide. It may be compounded in 503A pharmacies where allowed. It is not listed under a DEA schedule.

Overview

P21 is a synthetic tetra-peptide derived from the active region of ciliary neurotrophic factor (CNTF), specifically residues 148-151 with an adamantylated glycine modification for enhanced blood-brain barrier penetration. It functions as a cyclin-dependent kinase (CDK) inhibitor, binding to CDK1, CDK2, and CDK4/6 complexes to regulate cell cycle progression at G1 and S phases, while also promoting dentate gyrus neurogenesis and neuroprotection. P21 shows potential in research for neurological disorders like Alzheimer's disease through neurotrophic effects and memory enhancement via inhibition of leukemia inhibitory factor.

P21 is a synthetic tetrapeptide derived from the active region of ciliary neurotrophic factor (CNTF), specifically amino acid residues 148-151, with modifications like adamantane to enhance blood-brain barrier penetration and stability. As a cyclin-dependent kinase (CDK) inhibitor, it blocks CDK complexes, including the harmful CDK5/p25 pair, promoting cell cycle arrest, neuronal survival, and reduced apoptosis in preclinical models. It enhances dentate gyrus neurogenesis by inhibiting leukemia inhibitory factor (LIF) signaling and supports neuroplasticity, showing promise in slowing Alzheimer's disease progression through clearance of tau protein and beta-amyloid plaques. P21 also exhibits potential neuroprotective effects against cognitive decline, traumatic brain injury, and neurodegeneration, positioning it as a candidate for neurological therapeutics in early research.

Benefits

P21 upregulates brain-derived neurotrophic factor (BDNF) expression, its receptor TrkB, and CREB activation, enhancing neuronal plasticity, synaptic protein synthesis, dendritic spine formation, long-term potentiation, and memory consolidation in preclinical models.¹ It restores glutamate receptor subunit expression (GluN2A, GluN2B, GluA1-3), reverses synaptic dysfunction, promotes neurogenesis in aged and diseased states, and reduces tau hyperphosphorylation, amyloid-beta levels, and oxidative stress/apoptosis in Alzheimer's disease models, traumatic brain injury, and age-related cognitive decline.¹,²,³ These effects position P21 as a research tool for neuroprotection and cognitive enhancement in neurodegenerative conditions, with demonstrated efficacy in normalizing pathological protein accumulation and supporting neuronal survival without significant adverse effects in chronic animal studies.¹,⁴

Side effects

P21 administered subcutaneously is generally reported as safe at recommended dosages, with no severe side effects such as loss of appetite or body weight loss observed in studies.³ Common mild adverse effects include redness, pain, or swelling at the injection site, as well as initial digestive symptoms like nausea, vomiting, or diarrhea that typically resolve after a few doses.³,⁵ A key safety consideration is its potential to inhibit apoptosis, which may facilitate tumor growth, making active cancer a major contraindication.⁵ Use should occur under physician supervision with appropriate dosing, as P21 remains an investigational peptide.⁵ Pregnant women may use it safely, though it could cause moderate effects during breastfeeding, and it generally spares the kidneys, liver, and heart.⁶

Mechanisms of action

P21 acts as a cyclin-dependent kinase inhibitor (CDKI) by binding to cyclin-CDK complexes, such as CDK2, CDK1, and CDK4/6, through its N-terminal Cy1 motif, thereby blocking their activation and halting cell cycle progression primarily at the G1/S checkpoint.⁷,⁸ This inhibition prevents phosphorylation of retinoblastoma protein (pRb), repressing E2F-dependent transcription of genes required for S-phase entry.⁸,⁹ Often induced by p53 in response to DNA damage via p53-dependent pathways, P21 allows time for DNA repair by also interacting with proliferating cell nuclear antigen (PCNA) to inhibit replicative DNA synthesis while permitting nucleotide excision repair.⁷,⁸,⁹ In contexts of severe damage, P21 levels may decrease, facilitating apoptosis indirectly through CDK reactivation.⁸,¹⁰